Literature DB >> 26170750

Relationship of preoperative neutrophil lymphocyte ratio with prognosis in gastrointestinal stromal tumors.

Süleyman Kargın1, Murat Çakır2, Ebubekir Gündeş2, Yusuf Yavuz2, Hacı Hasan Esen3, M Sinan İyisoy4, Naile Kökbudak3, Tevfik Küçükkartallar2.   

Abstract

OBJECTIVE: Gastrointestinal stromal tumors are believed to play a role in immunosuppression with their local effect. In some cancers with associated inflammation, an increased pretreatment neutrophil lymphocyte ratio is considered as an indicator of poor prognosis. The aim of our study was to assess the relationship of increased blood neutrophil lymphocyte ratio with disease prognosis in patients with gastrointestinal stromal tumors.
MATERIAL AND METHODS: The data of 78 patients who underwent surgery with the diagnosis of primary gastrointestinal stromal tumor in our clinic were evaluated retrospectively. The preoperative neutrophil lymphocyte ratio in the peripheral blood was determined. The neutrophil lymphocyte ratio and its relationship with tumor risk and prognosis were compared. The data were evaluated by Pearson's correlation analysis and the Welch ANOVA test.
RESULTS: The preoperative neutrophil lymphocyte ratio was significantly increased in the high-risk groups (p<0.05). An increased preoperative neutrophil lymphocyte ratio was associated with shorter survival (r=-0.32, p=0.009). In addition, an increase in the neutrophil lymphocyte ratio was associated with an increase in the mitotic activity of the tumor (r=-0.364, p=0.025).
CONCLUSION: The preoperative neutrophil lymphocyte ratio in gastrointestinal stromal tumors can be used as an indicator of high-risk tumors and poor prognosis.

Entities:  

Keywords:  Gastrointestinal stromal tumor; neutrophil lymphocyte ratio; prognosis

Year:  2015        PMID: 26170750      PMCID: PMC4485812          DOI: 10.5152/UCD.2015.2840

Source DB:  PubMed          Journal:  Ulus Cerrahi Derg        ISSN: 1300-0705


  30 in total

1.  Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.

Authors:  H Joensuu; P J Roberts; M Sarlomo-Rikala; L C Andersson; P Tervahartiala; D Tuveson; S Silberman; R Capdeville; S Dimitrijevic; B Druker; G D Demetri
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

2.  Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.

Authors:  Edwin P Rock; Vicki Goodman; Janet X Jiang; Kooros Mahjoob; S Leigh Verbois; David Morse; Ramzi Dagher; Robert Justice; Richard Pazdur
Journal:  Oncologist       Date:  2007-01

Review 3.  Polymorphonuclear neutrophils and T lymphocytes: strange bedfellows or brothers in arms?

Authors:  Ingrid Müller; Markus Munder; Pascale Kropf; Gertrud Maria Hänsch
Journal:  Trends Immunol       Date:  2009-09-21       Impact factor: 16.687

4.  Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma.

Authors:  Karim J Halazun; Mark A Hardy; Abbas A Rana; David C Woodland; Elijah J Luyten; Suhari Mahadev; Piotr Witkowski; Abbey B Siegel; Robert S Brown; Jean C Emond
Journal:  Ann Surg       Date:  2009-07       Impact factor: 12.969

5.  Analysis of factors affecting recurrence of hepatocellular carcinoma after liver transplantation with a special focus on inflammation markers.

Authors:  Valentina Rosa Bertuzzo; Matteo Cescon; Matteo Ravaioli; Gian Luca Grazi; Giorgio Ercolani; Massimo Del Gaudio; Alessandro Cucchetti; Antonietta D'Errico-Grigioni; Rita Golfieri; Antonio Daniele Pinna
Journal:  Transplantation       Date:  2011-06-15       Impact factor: 4.939

6.  Prognostic value of an inflammation-based score in patients undergoing pre-operative chemotherapy followed by surgery for esophageal cancer.

Authors:  Hiroshi Miyata; Makoto Yamasaki; Yukinori Kurokawa; Shuji Takiguchi; Kiyokazu Nakajima; Yoshiyuki Fujiwara; Masaki Mori; Yuichiro Doki
Journal:  Exp Ther Med       Date:  2011-06-30       Impact factor: 2.447

7.  Correlation between the pretherapeutic neutrophil to lymphocyte ratio and the pathologic response to neoadjuvant chemotherapy in patients with advanced esophageal cancer.

Authors:  Hiroshi Sato; Yasuhiro Tsubosa; Tatsuyuki Kawano
Journal:  World J Surg       Date:  2012-03       Impact factor: 3.352

8.  Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

Authors:  Charles D Blanke; Cathryn Rankin; George D Demetri; Christopher W Ryan; Margaret von Mehren; Robert S Benjamin; A Kevin Raymond; Vivien H C Bramwell; Laurence H Baker; Robert G Maki; Michael Tanaka; J Randolph Hecht; Michael C Heinrich; Christopher D M Fletcher; John J Crowley; Ernest C Borden
Journal:  J Clin Oncol       Date:  2008-02-01       Impact factor: 44.544

9.  Assessment of the neutrophil to lymphocyte ratio in young patients with acute coronary syndromes.

Authors:  Serkan Oztürk; Alim Erdem; Mehmet Fatih Ozlü; Selim Ayhan; Kemalettin Erdem; Mehmet Ozyaşar; Yusuf Aslantaş; Mehmet Yazıcı
Journal:  Turk Kardiyol Dern Ars       Date:  2013-06

10.  A scoring model based on neutrophil to lymphocyte ratio predicts recurrence of HBV-associated hepatocellular carcinoma after liver transplantation.

Authors:  Guo-Ying Wang; Yang Yang; Hua Li; Jian Zhang; Nan Jiang; Min-Ru Li; Huan-Bing Zhu; Qi Zhang; Gui-Hua Chen
Journal:  PLoS One       Date:  2011-09-26       Impact factor: 3.240

View more
  1 in total

1.  Combination of PLR, MLR, MWR, and Tumor Size Could Significantly Increase the Prognostic Value for Gastrointestinal Stromal Tumors.

Authors:  Fan Feng; Yangzi Tian; Shushang Liu; Gaozan Zheng; Zhen Liu; Guanghui Xu; Man Guo; Xiao Lian; Daiming Fan; Hongwei Zhang
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.